+44 (0)1509 263171
Please use this identifier to cite or link to this item:
|Title: ||Synthesis and activity of a novel Autotaxin inhibitor-Icodextrin conjugate|
|Authors: ||Fisher, Natalie|
Edwards, Michael G.
Allin, Steven M.
Wallis, John D.
Page, Philip C. Bulman
McKenzie, Michael J.
Jones, Stefanie M.
Elsegood, Mark R.J.
|Issue Date: ||2018|
|Publisher: ||© American Chemical Society (ACS)|
|Citation: ||FISHER, N. ... et al., 2018. Synthesis and Activity of a Novel Autotaxin Inhibitor-Icodextrin Conjugate. Journal of Medicinal Chemistry, 61, pp. 7942-7951.|
|Abstract: ||© Copyright 2018 American Chemical Society. Autotaxin is an extracellular phospholipase D that catalyses the hydrolysis of lysophosphatidyl choline (LPC) to generate the bioactive lipid lysophosphatidic acid (LPA). Autotaxin has been implicated in many pathological processes relevant to cancer. Intraperitoneal administration of an autotaxin inhibitor may benefit patients with ovarian cancer, however low molecular mass compounds are known to be rapidly cleared from the peritoneal cavity. Icodextrin is a polymer that is already in clinical use because it is slowly eliminated from the peritoneal cavity. Herein we report conjugation of the autotaxin inhibitor HA-155 to icodextrin. The conjugate inhibits autotaxin activity (IC50 = 0.86 ± 0.13 μg mL-1) and reduces cell migration. Conjugation of the inhibitor increased its solubility, decreased its membrane permeability and improved its intraperitoneal retention in mice. These observations demonstrate the first application of icodextrin as a covalently-bonded drug delivery platform with potential use in the treatment of ovarian cancer.|
|Description: ||This paper is in closed access until 30th July 2019.|
|Sponsor: ||This research was supported by MRC (grant G1100184).|
|Version: ||Accepted for publication|
|Publisher Link: ||https://doi.org/10.1021/acs.jmedchem.8b00935|
|Appears in Collections:||Closed Access (Chemistry)|
Files associated with this item:
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.